{"id":"NCT01861522","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","officialTitle":"A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2013-05-23","resultsPosted":"2015-12-15","lastUpdate":"2015-12-15"},"enrollment":473,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Perennial Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Bepotastine besilate","otherNames":["TALION 5mg tablets"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TAU-284","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis and to investigate safety of TAU-284.","primaryOutcome":{"measure":"Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]","timeFrame":"Baseline and Week 2","effectByArm":[{"arm":"TAU-284","deltaMin":-1.579,"sd":0.09},{"arm":"Placebo","deltaMin":-1.11,"sd":0.092}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":2,"countries":["Japan"]},"refs":{"pmids":["26364765"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":240},"commonTop":["Pharyngitis","Nasopharyngitis"]}}